Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
Robert ZilberszacRishi ChandiramaniChristian HengstenbergSamantha SartoriDavide CaoJaya ChandrasekharUlrich SchäferDidier TchetcheRoberto VioliniRaban JegerEric Van BellePeter BoekstegersRainer HambrechtChristophe TronNicolas DumenteilAxel LinkeJurriën M Ten BergEfthymios N DeliargyrisProdromos AnthopoulosRoxana MehranGeorge D DangasPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
Patients with PAD undergoing transfemoral TAVR did not exhibit an increased risk of any major adverse events, according to the procedural anticoagulant randomization. However, patients treated with Bivalirudin had significantly higher rates of minor vascular complications.
Keyphrases
- transcatheter aortic valve replacement
- percutaneous coronary intervention
- venous thromboembolism
- atrial fibrillation
- aortic stenosis
- direct oral anticoagulants
- aortic valve
- transcatheter aortic valve implantation
- aortic valve replacement
- coronary artery disease
- acute coronary syndrome
- catheter ablation
- ejection fraction
- risk factors
- growth factor
- left ventricular